DPP-4 inhibitors increasing IBD
A recent data-mining study found a significant association between starting DPP-4 (dipeptidyl peptidase-4) inhibitors for diabetes and the later development of inflammatory bowel disease (see dm dpp4 and ibd bmj2018 in dropbox , or doi.org/10.1136/bmj.k872 . Details: --141,170 patients >18yo starting antidiabetic meds, from 2007-2016, and followed a median of 3.6 years. from the United Kingdom Clinical Practice Research Datalink of >700 general practices . --mean age 62, 15% with BMI >30, 15% alcohol-related disorders , 16% current smokers, 31% A1c>8% --primary outcome: adjusted hazard ratio for incident inflammatory bowel disease (IBD) with use of DPP-4 inhibitors vs other diabetes meds --30,488 (21.6%) received script for DPP-4 inhibitors; median duration of use =1.6 yrs --patients on DPP-4 inhibitors: older (66 vs 61yo), more likely to have higher A1c concentration (A1c>8% in 44% vs 30%), longer du...